The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023.
Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025.
Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit.
Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion.
Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.
Persons:
Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta
Organizations:
Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $
Locations:
Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York